Lynx1 Capital Management’s TScan Therapeutics TCRX Stock Holding History

Lynx1 Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.1M	Hold	8,019,148	–	–	1.28%	8
2025 Q4	$8.02M	Buy	8,019,148 +161,801	+2%	+$234K	1.62%	8
2025 Q3	$14.3M	Hold	7,857,347	–	–	2.91%	7
2025 Q2	$11.4M	Buy	7,857,347 +2,500,000	+47%	+$3.61M	3.29%	7
2025 Q1	$7.39M	Hold	5,357,347	–	–	2.65%	8
2024 Q4	$16.3M	Buy	5,357,347 +132,747	+3%	+$602K	6.11%	6
2024 Q3	$26M	Hold	5,224,600	–	–	9.22%	5
2024 Q2	$30.6M	Hold	5,224,600	–	–	11.03%	5
2024 Q1	$41.5M	Hold	5,224,600	–	–	10.68%	4
2023 Q4	$30.5M	Hold	5,224,600	–	–	11.98%	4
2023 Q3	$13.4M	Hold	5,224,600	–	–	8.85%	5
2023 Q2	$13.1M	Buy	+5,224,600	New	+$14M	8.56%	5

Other funds holding TCRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Lynx1 Capital Management's TCRX Position: Q1 2026 in Review

Lynx1 Capital Management held its TScan Therapeutics (TCRX) position steady in Q1 2026 at 8,019,148 shares worth $8.1M. The position accounts for 1.28% of the portfolio, ranked #8.

Lynx1 Capital Management first reported a position in TCRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $41.5M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

Lynx1 Capital Management held 8,019,148 shares of TScan Therapeutics worth $8.1M as of Q1 2026.
Lynx1 Capital Management left its TScan Therapeutics share count unchanged in Q1 2026.
TScan Therapeutics made up 1.28% of Lynx1 Capital Management's portfolio in Q1 2026, its #8 holding.
Lynx1 Capital Management first reported a position in TScan Therapeutics in Q2 2023 and has held it in 12 quarters since.
Lynx1 Capital Management's TScan Therapeutics position peaked at $41.5M in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Lynx1 Capital Management's 13F filing for Q1 2026, filed 4 May 2026.